|
|
 Previous Article | Table of Contents | Next Article 
Differential Incorporation of Ara-C, Gemcitabine, and Fludarabine Into Replicating and Repairing DNA in Proliferating Human Leukemia Cells
Hiromichi Iwasaki,
Peng Huang,
Michael J. Keating, and
William Plunkett
From the Departments of Clinical Investigation and Hematology, The University of Texas MD Anderson Cancer Center, Houston.
The major actions of nucleoside analogs such as arabinosylcytosine (ara-C) and fludarabine occurs after their incorporation into DNA, during either replication or repair synthesis. The metabolic salvage and DNA incorporation of the normal nucleoside, deoxycytidine, is functionally compartmentalized toward repair synthesis in a process regulated by ribonucleotide reductase. The aim of this study was to investigate the metabolic pathways by which nucleoside analogs that do (fludarabine, gemcitabine) or do not (ara-C) affect ribonucleotide reductase are incorporated into DNA in proliferating human leukemia cells. Using alkaline density-gradient centrifugation to separate repaired DNA from replicating DNA and unreplicated parental DNA strands, approximately 60% of ara-C nucleotide in DNA was incorporated by repair synthesis in CCRF-CEM cells; the remainder was incorporated by replication. In contrast, fludarabine and gemcitabine, nucleosides that inhibit ribonucleotide reductase and decreased deoxynucleotide pools, were incorporated mainly within replicating DNA. Hydroxyurea also depleted deoxynucleotide pools and increased the incorporation of ara-C into DNA by replicative synthesis. Stimulation of DNA repair activity by UV irradiation selectively enhanced the incorporation of all nucleosides tested through repair synthesis. These findings suggest that the pathways by which therapeutically useful nucleoside analogs are incorporated into DNA are affected by cellular dNTP pools from de novo synthesis and by the relative activities of DNA repair and replication. The antitumor activity of these drugs may be enhanced by combination with either ribonucleotide reductase inhibitors to increase their incorporation into replicating DNA or with agents that induce DNA damage and evoke the DNA repair process.
Blood, Vol. 90 No. 1 (July 1), 1997:
pp. 270-278
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. B. Klisovic, W. Blum, X. Wei, S. Liu, Z. Liu, Z. Xie, T. Vukosavljevic, C. Kefauver, L. Huynh, J. Pang, et al.
Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia
Clin. Cancer Res.,
June 15, 2008;
14(12):
3889 - 3895.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. G. Maki
Gemcitabine and Docetaxel in Metastatic Sarcoma: Past, Present, and Future
Oncologist,
August 1, 2007;
12(8):
999 - 1006.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Giovannetti, V. Mey, R. Danesi, I. Mosca, and M. Del Tacca
Synergistic Cytotoxicity and Pharmacogenetics of Gemcitabine and Pemetrexed Combination in Pancreatic Cancer Cell Lines
Clin. Cancer Res.,
May 1, 2004;
10(9):
2936 - 2943.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Pourquier, C. Gioffre, G. Kohlhagen, Y. Urasaki, F. Goldwasser, L. W. Hertel, S. Yu, R. T. Pon, W. H. Gmeiner, and Y. Pommier
Gemcitabine (2',2'-Difluoro-2'-Deoxycytidine), an Antimetabolite That Poisons Topoisomerase I
Clin. Cancer Res.,
August 1, 2002;
8(8):
2499 - 2504.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. C. Pagliaro, R. E. Millikan, S.-M. Tu, D. Williams, D. Daliani, C. N. Papandreou, and C. J. Logothetis
Cisplatin, Gemcitabine, and Ifosfamide As Weekly Therapy: A Feasibility and Phase II Study of Salvage Treatment for Advanced Transitional-Cell Carcinoma
J. Clin. Oncol.,
July 1, 2002;
20(13):
2965 - 2970.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Leonce, V. Perez, S. Lambel, D. Peyroulan, F. Tillequin, S. Michel, M. Koch, B. Pfeiffer, G. Atassi, J. A Hickman, et al.
Induction of Cyclin E and Inhibition of DNA Synthesis by the Novel Acronycine Derivative S23906-1 Precede the Irreversible Arrest of Tumor Cells in S Phase Leading to Apoptosis
Mol. Pharmacol.,
December 1, 2001;
60(6):
1383 - 1391.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Liekens, J. Neyts, E. De Clercq, E. Verbeken, D. Ribatti, and M. Presta
Inhibition of Fibroblast Growth Factor-2-induced Vascular Tumor Formation by the Acyclic Nucleoside Phosphonate Cidofovir
Cancer Res.,
July 1, 2001;
61(13):
5057 - 5064.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Azuma, P. Huang, A. Matsuda, and W. Plunkett
2'-C-Cyano-2'-deoxy-1-{beta}-D-arabino-pentofuranosylcytosine: A Novel Anticancer Nucleoside Analog that Causes Both DNA Strand Breaks and G2 Arrest
Mol. Pharmacol.,
April 1, 2001;
59(4):
725 - 731.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J. W. G. van Putten, H. J. M. Groen, K. Smid, G. J. Peters, and H. H. Kampinga
End-joining Deficiency and Radiosensitization Induced by Gemcitabine
Cancer Res.,
February 1, 2001;
61(4):
1585 - 1591.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
P. L. Zinzani, G. Baliva, M. Magagnoli, M. Bendandi, G. Modugno, F. Gherlinzoni, G. F. Orcioni, S. Ascani, R. Simoni, S. A. Pileri, et al.
Gemcitabine Treatment in Pretreated Cutaneous T-Cell Lymphoma: Experience in 44 Patients
J. Clin. Oncol.,
July 1, 2000;
18(13):
2603 - 2606.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L.-Y. Yang, L. Li, H. Jiang, Y. Shen, and W. Plunkett
Expression of ERCC1 Antisense RNA Abrogates Gemcitabine-mediated Cytotoxic Synergism with Cisplatin in Human Colon Tumor Cells Defective in Mismatch Repair but Proficient in Nucleotide Excision Repair
Clin. Cancer Res.,
March 1, 2000;
6(3):
773 - 781.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
E. G. Bridges, Z. Jiang, and Y.-c. Cheng
Characterization of a dCTP Transport Activity Reconstituted from Human Mitochondria
J. Biol. Chem.,
February 19, 1999;
274(8):
4620 - 4625.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Zhu, M. Johansson, and A. Karlsson
Incorporation of Nucleoside Analogs into Nuclear or Mitochondrial DNA Is Determined by the Intracellular Phosphorylation Site
J. Biol. Chem.,
August 25, 2000;
275(35):
26727 - 26731.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
